Literature DB >> 3536078

Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease.

G L Bianchi Scarrà, M Romani, D A Coviello, C Garrè, R Ravazzolo, G Vidali, F Ajmar.   

Abstract

Two erythroid markers, acetylcholinesterase and hemoglobin, can be reversibly induced in the K-562 cell line after sodium butyrate treatment. In the present paper we show that 1-beta-D-arabinofuranosylcytosine (ara-C), induces the coordinate, irreversible expression of these two erythroid markers. This induction occurs at an ara-C concentration (0.05 mM) that results in K-562 cytostasis and is accompanied by deep morphological changes of cells. The differentiated phenotype is independent of the K-562 cell clone used [K-562, K-562 (S), K-562 (S)P] and is associated with the loss of cell renewal capacity. Continuous presence of the inducer is not necessary to achieve terminal differentiation. In contrast to what is seen for other inducers (sodium butyrate and hemin), one of the early effects of ara-C treatment is the marked decrease of c-myc mRNA expression after the first 4 hours of induction, whereas N-ras and histone 4 expression remain constant during the first 48 h. Our results suggest that ara-C treatment can irreversibly activate the erythroid differentiative program of K-562 cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536078

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.

Authors:  E Olah; Y Natsumeda; T Ikegami; Z Kote; M Horanyi; J Szelenyi; E Paulik; T Kremmer; S R Hollan; J Sugar
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 2.  The HL60 cell line: a model system for studying human myeloid cell differentiation.

Authors:  G D Birnie
Journal:  Br J Cancer Suppl       Date:  1988-12

3.  The plasticity and potential of leukemia cell lines to differentiate into dendritic cells.

Authors:  Qingwei Guo; Leling Zhang; Fu Li; Guosheng Jiang
Journal:  Oncol Lett       Date:  2012-07-25       Impact factor: 2.967

4.  Molecular identification of a major palmitoylated erythrocyte membrane protein containing the src homology 3 motif.

Authors:  P Ruff; D W Speicher; A Husain-Chishti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

5.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo.

Authors:  Shiwu Zhang; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Cancer Lett       Date:  2013-01-29       Impact factor: 8.679

7.  Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin.

Authors:  G Feriotto; C Nastruzzi; R Barbieri; R Gambari
Journal:  Blut       Date:  1988-07

Review 8.  Generation of erythroid cells from polyploid giant cancer cells: re-thinking about tumor blood supply.

Authors:  Zhigang Yang; Hong Yao; Fei Fei; Yuwei Li; Jie Qu; Chunyuan Li; Shiwu Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-07       Impact factor: 4.553

9.  Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience.

Authors:  Yasir Bashir; Sajjad Geelani; Nusrat Bashir; Shabeer A Mir; Mosin Mushtaq; M Aleem Jan; Javid Rasool
Journal:  South Asian J Cancer       Date:  2015 Jan-Mar

10.  Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness.

Authors:  Linu A Jacob; S Aparna; K C Lakshmaiah; D Lokanatha; Govind Babu; Suresh Babu; Sandhya Appachu
Journal:  Adv Hematol       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.